|
|
| (13 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {| style="border: 2px solid #4479BA; align="left" | | {| class="wikitable" |
| ! colspan=2 style="width: 400px; background: #4479BA; text-align: left;"|{{fontcolor|#FFF|Hepatic Laboratory Abnormalities—Study GS-US-540-5773}}
| | |+ |
| ! style="width: 200px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Remdesivir for 5 Days}} | | ! colspan="2" | |
| ! style="width: 200px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Remdesivir for 10 Days}}
| |
| ! style="width: 200px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Total}}
| |
| |- | | |- |
| | rowspan=2 style="padding: 0 5px; background: #F5F5F5; text-align: left;" | ALT Increased | | | |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Grade 3
| | | |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 8/194 (4%) | |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 11/191 (6%)
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 19/385 (5%)
| |
| |- | | |- |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Grade 4 | | | |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 4/194 (2%)
| | | |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 5/191 (3%)
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 9/385 (2%) | |
| |- | | |- |
| | rowspan=2 style="padding: 0 5px; background: #F5F5F5; text-align: left;" | AST Increased | | | colspan="2" | |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Grade 3
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 11/194 (6%)
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 7/190 (4%)
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 18/384 (5%)
| |
| |-
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Grade 4
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 3/194 (2%)
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 4/190 (2%)
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 7/384 (2%)
| |
| |-
| |
| | rowspan=2 style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Total Bilirubin Increased
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Grade 3
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 1/193 (1%)
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 3/190 (2%)
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 4/383 (1%)
| |
| |-
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Grade 4
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 0
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 1/190 (1%)
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 1/383 (<1%)
| |
| |- | | |- |
| | | colspan="2" | |
| |} | | |} |